一项名为“ASAP（尽可能快）”的试验对国际治疗标准提出了新的见解：对于急性髓系白血病（Acute Myeloid Leukemia, AML）患者，高剂量化疗并非移植前的必要步骤，这意味着患者可以更快地进行移植 [1]。

New research maps how bone marrow changes in acute myeloid leukemia disrupt neutrophil development and boost the risk for ...

Results of a recently published long-term follow-up of the ASAP trial, which was conducted at universities and clinics across ...

The Company has submitted a supplemental New Drug Application (sNDA) seeking the approval of revumenib for the treatment of R/R mNPM1 AML. The sNDA has been granted Priority Review by the FDA and ...

A research team at Lund University in Sweden has discovered a mechanism that helps acute myeloid leukemia cells to evade the ...

CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical ...